Several analysts have recently updated their ratings and price targets for Teva Pharmaceutical Industries (NYSE: TEVA):

  • 1/5/2018 – Teva Pharmaceutical Industries was downgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “underperform” rating. They now have a $17.00 price target on the stock, down previously from $19.58.
  • 1/4/2018 – Teva Pharmaceutical Industries was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $24.00 price target on the stock.
  • 1/3/2018 – Teva Pharmaceutical Industries was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 1/2/2018 – Teva Pharmaceutical Industries is now covered by analysts at Leerink Swann. They set an “underperform” rating and a $15.00 price target on the stock.
  • 1/2/2018 – Teva Pharmaceutical Industries was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Meanwhile, Teva cut its sales and earnings guidance twice this year. Also, Teva’s shares underperformed the generic industry in 2017. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years. However, these efforts might not prove to be enough to revive the company’s fortunes during this challenging period, especially as it faces erosion of its largest product, Copaxone.”
  • 12/28/2017 – Teva Pharmaceutical Industries was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 12/18/2017 – Teva Pharmaceutical Industries was given a new $20.00 price target on by analysts at UBS Group AG. They now have a “hold” rating on the stock.
  • 12/15/2017 – Teva Pharmaceutical Industries was given a new $13.00 price target on by analysts at Royal Bank of Canada. They now have a “sell” rating on the stock.
  • 12/15/2017 – Teva Pharmaceutical Industries was given a new $20.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 12/15/2017 – Teva Pharmaceutical Industries was upgraded by analysts at Credit Suisse Group AG from an “underperform” rating to a “neutral” rating. They now have a $20.00 price target on the stock, up previously from $8.00.
  • 12/15/2017 – Teva Pharmaceutical Industries was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating. They now have a $18.00 price target on the stock.
  • 12/15/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at BTIG Research to $20.00.
  • 12/15/2017 – Teva Pharmaceutical Industries was upgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “buy” rating. They now have a $20.00 price target on the stock.
  • 12/14/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Wells Fargo & Co.
  • 12/14/2017 – Teva Pharmaceutical Industries was given a new $16.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 12/14/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 12/14/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs.””
  • 12/12/2017 – Teva Pharmaceutical Industries is now covered by analysts at Guggenheim. They set a “neutral” rating and a $16.00 price target on the stock.
  • 12/5/2017 – Teva Pharmaceutical Industries was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/29/2017 – Teva Pharmaceutical Industries was given a new $11.00 price target on by analysts at Royal Bank of Canada. They now have a “sell” rating on the stock.
  • 11/29/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at Mizuho from $12.00 to $16.00. They now have a “neutral” rating on the stock.
  • 11/28/2017 – Teva Pharmaceutical Industries was given a new $16.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 11/27/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/25/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/17/2017 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $12.00 price target on the stock, down previously from $15.00.
  • 11/14/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/13/2017 – Teva Pharmaceutical Industries was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $11.00 price target on the stock, down previously from $11.48.
  • 11/12/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..

Shares of Teva Pharmaceutical Industries Ltd (TEVA) traded down $0.19 during mid-day trading on Monday, hitting $19.03. The stock had a trading volume of 9,350,000 shares, compared to its average volume of 25,550,000. The company has a market cap of $19,200.00, a price-to-earnings ratio of -3.24, a P/E/G ratio of 1.36 and a beta of 0.54. Teva Pharmaceutical Industries Ltd has a 12-month low of $10.85 and a 12-month high of $37.94. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a $0.085 dividend. The ex-dividend date was Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.79%. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.27%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.